NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS), comprehensive genomic profiling, and advanced assays like RaDaR ST for molecular residual disease (MRD) detection in solid tumors and PanTracer Pro for integrated diagnostics in advanced-stage cancers. The company provides clinical cancer testing, professional interpretation by pathologists and molecular experts, clinical trials support, research services, validation laboratory services, and oncology data solutions to pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, and managed care organizations across the United States and Europe. NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in multiple U.S. locations and the United Kingdom, with its Pharma Services Division supporting drug development for pharmaceutical clients. Founded in 1998 and headquartered in Fort Myers, Florida, NeoGenomics plays a key role in precision oncology by enabling personalized cancer diagnosis and treatment.